In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

By Nancy Lapid (Reuters) -Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer, according to ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

GRADE randomized 5,047 people with type 2 diabetes using metformin at baseline ... (Victoza), or the DPP-4 inhibitor sitagliptin (Januvia). It assessed multiple endpoints and reported that insulin ...

Sitagliptin (Januvia; Merck), the only marketed DPP4 ... With 394 candidates in development in 2006, (344 in 2005), diabetes is second only to cancer in R&D focus 3. This is not surprising given ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an analysis of MRK stock now.

They can recommend ways to help manage this side effect. Rybelsus may be used with other drugs for diabetes, but Januvia isn’t commonly used with it. Januvia is an alternative treatment for type ...

The new lower Medicare prices for the first 10 drugs won't go into effect until January 2026, but the discounts range from 79% for diabetes drug Januvia to 38% for blood cancer drug Imbruvica.

President Donald J. Trump recently announced a new prescription drug policy. It turns out the United States has been ripped ...

The global populating is aging, and approximately 29% of people with diabetes worldwide are aged 65 years and older, ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

More than 1.2 million Americans are diagnosed with a form of diabetes each year, and the numbers keep rising, making it one of the country’s biggest health crises. But new treatments are rapidly ...